| 1 |
Olumba FC, Zhou F, Park Y, Chapman WC; RESTORE Investigators Group. Normothermic Machine Perfusion for Declined Livers: A Strategy to Rescue Marginal Livers for Transplantation. J Am Coll Surg 2023;236:614-25. [PMID: 36728302 DOI: 10.1097/XCS.0000000000000555] [Reference Citation Analysis]
|
| 2 |
Sun Z, Han X, You W, Tang J, Xu J, Ye B, Li T, Zhang Y, Chen K, Ding Y, Wang W. Adjuvant therapy for cholangiocarcinoma after surgery and prognosis factors for cholangiocarcinoma: A single-center retrospective cohort study. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1116338] [Reference Citation Analysis]
|
| 3 |
Bo Z, Chen B, Yang Y, Yao F, Mao Y, Yao J, Yang J, He Q, Zhao Z, Shi X, Chen J, Yu Z, Yang Y, Wang Y, Chen G. Machine learning radiomics to predict the early recurrence of intrahepatic cholangiocarcinoma after curative resection: A multicentre cohort study. Eur J Nucl Med Mol Imaging 2023. [PMID: 36922449 DOI: 10.1007/s00259-023-06184-6] [Reference Citation Analysis]
|
| 4 |
Golino JL, Wang X, Maeng HM, Xie C. Revealing the Heterogeneity of the Tumor Ecosystem of Cholangiocarcinoma through Single-Cell Transcriptomics. Cells 2023;12:862. [DOI: 10.3390/cells12060862] [Reference Citation Analysis]
|
| 5 |
Byeon SJ, Chang MS, Cho HJ, Park JH, Kim KH, Park JH, Choi IS, Kim W, Han DS, Ahn HS, Heo SC. Prognostic roles of leptin-signaling proteins, PD-L1, and tumor-infiltrating lymphocytes in surgically-resected biliary tract cancers. J Surg Oncol 2023;127:587-97. [PMID: 36367404 DOI: 10.1002/jso.27140] [Reference Citation Analysis]
|
| 6 |
Mauro E, Ferrer-Fàbrega J, Sauri T, Soler A, Cobo A, Burrel M, Iserte G, Forner A. New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy. Cancers (Basel) 2023;15. [PMID: 36831586 DOI: 10.3390/cancers15041244] [Reference Citation Analysis]
|
| 7 |
Zeng L, He C, Li X. Prognosis for intrahepatic cholangiocarcinoma after liver transplantation by size of tumor. Surgery 2023:S0039-6060(22)01042-X. [PMID: 36792459 DOI: 10.1016/j.surg.2022.12.014] [Reference Citation Analysis]
|
| 8 |
Sposito C, Ratti F, Cucchetti A, Ardito F, Ruzzenente A, Di Sandro S, Maspero M, Ercolani G, Di Benedetto F, Guglielmi A, Giuliante F, Aldrighetti L, Mazzaferro V. Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma. J Hepatol 2023;78:356-63. [PMID: 36328332 DOI: 10.1016/j.jhep.2022.10.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Shenoy A, Pan JJ, Fontana RJ. PRO: Liver transplantation for intrahepatic cholangiocarcinoma. Clin Liver Dis (Hoboken) 2023;21:56-9. [PMID: 36938313 DOI: 10.1002/cld.1252] [Reference Citation Analysis]
|
| 10 |
Liao W, Feng Q, Liu H, Du J, Chen X, Zeng Y. Circular RNAs in cholangiocarcinoma. Cancer Lett 2023;553:215980. [PMID: 36336149 DOI: 10.1016/j.canlet.2022.215980] [Reference Citation Analysis]
|
| 11 |
Aliseda D, Martí-Cruchaga P, Zozaya G, Rodríguez-Fraile M, Bilbao JI, Benito-Boillos A, Martínez De La Cuesta A, Lopez-Olaondo L, Hidalgo F, Ponz-Sarvisé M, Chopitea A, Rodríguez J, Iñarrairaegui M, Herrero JI, Pardo F, Sangro B, Rotellar F. Liver Resection and Transplantation Following Yttrium-90 Radioembolization for Primary Malignant Liver Tumors: A 15-Year Single-Center Experience. Cancers (Basel) 2023;15. [PMID: 36765691 DOI: 10.3390/cancers15030733] [Reference Citation Analysis]
|
| 12 |
Miao GY, Qian XL, Zhang YF, Wu F, Huang P, Wang F, Zhou CW, Lu X, Yang C, Zeng MS. A nomogram based on radiomics to predict microvascular invasion and overall survival in intrahepatic cholangiocarcinoma.. [DOI: 10.21203/rs.3.rs-2482282/v1] [Reference Citation Analysis]
|
| 13 |
Sae-Fung A, Mutirangura A, Jitkaew S. Identification and validation of a novel ferroptosis-related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma. Front Immunol 2022;13:1051273. [PMID: 36733386 DOI: 10.3389/fimmu.2022.1051273] [Reference Citation Analysis]
|
| 14 |
Olthof PB, Arntz P, Truant S, El Amrani M, Dasari BVM, Tomassini F, Troisi RI, Bennink RJ, Grunhagen D, Chapelle T, Op de Beeck B, Zanoni L, Serenari M, Erdmann JI. Hepatobiliary scintigraphy to predict postoperative liver failure after major liver resection; a multicenter cohort study in 547 patients. HPB (Oxford) 2023:S1365-182X(22)01680-X. [PMID: 36759303 DOI: 10.1016/j.hpb.2022.12.005] [Reference Citation Analysis]
|
| 15 |
Sukphokkit S, Kiatwuthinon P, Kumkate S, Janvilisri T. Distinct cholangiocarcinoma cell migration in 2D monolayer and 3D spheroid culture based on galectin-3 expression and localization. Front Oncol 2022;12:999158. [PMID: 36713574 DOI: 10.3389/fonc.2022.999158] [Reference Citation Analysis]
|
| 16 |
Wang Z, Wu S, Wang G, Yang Z, Zhang Y, Zhu C, Qin X. ARHGAP21 Is Involved in the Carcinogenic Mechanism of Cholangiocarcinoma: A Study Based on Bioinformatic Analyses and Experimental Validation. Medicina (Kaunas) 2023;59. [PMID: 36676763 DOI: 10.3390/medicina59010139] [Reference Citation Analysis]
|
| 17 |
Hu S, Xia C, Zou H, Ren W, Liu L, Wang L, Kang Q, He K, Wang T, Zhang X. HS6ST1 overexpressed in cancer-associated fibroblast and inhibited cholangiocarcinoma progression. Dig Liver Dis 2022:S1590-8658(22)00831-3. [PMID: 36586771 DOI: 10.1016/j.dld.2022.12.007] [Reference Citation Analysis]
|
| 18 |
Miao X, Hu J, Chai C, Tang H, Zhao Z, Luo W, Zhou W, Xu H. Establishment and characterization of a new intrahepatic cholangiocarcinoma cell line derived from a Chinese patient. Cancer Cell Int 2022;22:418. [PMID: 36578029 DOI: 10.1186/s12935-022-02840-3] [Reference Citation Analysis]
|
| 19 |
Kupietzky A, Ariche A. Surgical Aspects of Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2022;14. [PMID: 36551749 DOI: 10.3390/cancers14246265] [Reference Citation Analysis]
|
| 20 |
Hare AE, Makary MS. Locoregional Approaches in Cholangiocarcinoma Treatment. Cancers (Basel) 2022;14. [PMID: 36497334 DOI: 10.3390/cancers14235853] [Reference Citation Analysis]
|
| 21 |
Li Q, Chang Z, Wang T, Liu B, Wang X, Ge XY, Yang T, Liu Q, Wang W. Synergy of Losartan and chemotherapy for patients with cholangiocarcinoma: A propensity score-matched analysis. Front Oncol 2022;12:989080. [PMID: 36505810 DOI: 10.3389/fonc.2022.989080] [Reference Citation Analysis]
|
| 22 |
Connor AA, Kodali S, Abdelrahim M, Javle MM, Brombosz EW, Ghobrial RM. Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkers. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.996710] [Reference Citation Analysis]
|
| 23 |
Li X, Zhao C, Zhou E, Lin X. Efficacy and safety of adjuvant chemotherapy in T1N0M0 intrahepatic cholangiocarcinoma after radical resection. BMC Cancer 2022;22:1159. [DOI: 10.1186/s12885-022-10269-0] [Reference Citation Analysis]
|
| 24 |
Pevner JL, Tanvetyanon T. Prognostic Value of Positron Emission Tomography in Advanced Cholangiocarcinoma: A Single-Institution Study and Literature Review. Cureus 2022. [DOI: 10.7759/cureus.31026] [Reference Citation Analysis]
|
| 25 |
Rimini M, Loi E, Fabregat-franco C, Burgio V, Lonardi S, Niger M, Scartozzi M, Raposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Rizzato M, Nichetti F, Lai E, Cappetta A, Macarulla T, Fassan M, De Braud F, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Patrizia Z, Casadei-gardini A. Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters. European Journal of Cancer 2022;175:299-310. [DOI: 10.1016/j.ejca.2022.08.026] [Reference Citation Analysis]
|
| 26 |
Lai Q, Lerut J. A Western World Perspective of Survival Benefit of Living Donor Liver Transplantation: A Commentary to the Article by Jackson et al. Published in JAMA Surgery. Transpl Int 2022;35. [DOI: 10.3389/ti.2022.10931] [Reference Citation Analysis]
|
| 27 |
Peng M, Huang Y, Shen C, Yu W, Li H, Gu J. Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma.. [DOI: 10.21203/rs.3.rs-2152853/v1] [Reference Citation Analysis]
|
| 28 |
Zhang Y, Esmail A, Mazzaferro V, Abdelrahim M. Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision. Cancers 2022;14:5074. [DOI: 10.3390/cancers14205074] [Reference Citation Analysis]
|
| 29 |
Feng Q, Sun B, Xue T, Li R, Lin C, Gao Y, Sun L, Zhuo Y, Wang D. Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers. Front Immunol 2022;13:1025608. [PMID: 36341440 DOI: 10.3389/fimmu.2022.1025608] [Reference Citation Analysis]
|
| 30 |
Menon N, Mandelkern M. Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors. Dig Dis Sci 2022;67:4633-53. [PMID: 35908126 DOI: 10.1007/s10620-022-07616-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 31 |
Yuan P, Song J, Wang F, Zhu G, Chen B. Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma. Invest New Drugs 2022;40:1125-32. [PMID: 35793038 DOI: 10.1007/s10637-022-01257-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 32 |
Yao X, Chen B, Wang M, Zhang S, He B, Shi Z, Deng T, Bao W, Wang Y, Chen G, Bo Z. Exploration and validation of a novel ferroptosis-related gene signature predicting the prognosis of intrahepatic cholangiocarcinoma. Acta Biochim Biophys Sin (Shanghai) 2022;54:1376-85. [PMID: 36111744 DOI: 10.3724/abbs.2022125] [Reference Citation Analysis]
|
| 33 |
Elvevi A, Laffusa A, Scaravaglio M, Rossi RE, Longarini R, Stagno AM, Cristoferi L, Ciaccio A, Cortinovis DL, Invernizzi P, Massironi S. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol 2022;27:100737. [PMID: 35809836 DOI: 10.1016/j.aohep.2022.100737] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 34 |
Gravely AK, Vibert E, Sapisochin G. Surgical treatment of intrahepatic cholangiocarcinoma. J Hepatol 2022;77:865-7. [PMID: 35676107 DOI: 10.1016/j.jhep.2022.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 35 |
Liu Z, Yi J, Yang J, Zhang X, Wang L, Liu S. Diagnostic and prognostic nomograms for newly diagnosed intrahepatic cholangiocarcinoma with brain metastasis: A population-based analysis. Exp Biol Med (Maywood) 2022;247:1657-69. [PMID: 35946168 DOI: 10.1177/15353702221113828] [Reference Citation Analysis]
|
| 36 |
Zhang N, Yu BR, Wang YX, Zhao YM, Zhou JM, Wang M, Wang LR, Lin ZH, Zhang T, Wang L. Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma. J Dig Dis 2022;23:535-45. [PMID: 36148493 DOI: 10.1111/1751-2980.13127] [Reference Citation Analysis]
|
| 37 |
Zhou T, Mahn R, Möhring C, Sadeghlar F, Meyer C, Toma M, Kreppel B, Essler M, Glowka T, Matthaei H, Kalff JC, Strassburg CP, Gonzalez-carmona MA. Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate. Front Oncol 2022;12:933943. [DOI: 10.3389/fonc.2022.933943] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 38 |
Liu X, Jiang Y, Sun X, Zhao J, Zhang L, Jing X. Prognostic Significance of the Systemic Immune-Inflammation Index in Patients With Cholangiocarcinoma: A Meta-Analysis. Front Oncol 2022;12:938549. [DOI: 10.3389/fonc.2022.938549] [Reference Citation Analysis]
|
| 39 |
Xie J, Pu X, He J, Qiu Y, Lu C, Gao W, Wang X, Lu H, Shi J, Xu Y, Madabhushi A, Fan X, Chen J, Xu J. Survival prediction on intrahepatic cholangiocarcinoma with histomorphological analysis on the whole slide images. Computers in Biology and Medicine 2022;146:105520. [DOI: 10.1016/j.compbiomed.2022.105520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 40 |
Jiao CY, Zhang H, Ji GW, Xu Q, Lu M, Zhang B, Yang Y, Wang XH, Li XC. CT-based clinico-radiological nomograms for prognosis prediction in patients with intrahepatic mass-forming cholangiocarcinoma: a multi-institutional study. Eur Radiol 2022. [PMID: 35708837 DOI: 10.1007/s00330-022-08914-0] [Reference Citation Analysis]
|
| 41 |
Chen J, Gao Z, Li X, Shi Y, Tang Z, Liu W, Zhang X, Huang A, Luo X, Gao Q, Ding G, Song K, Zhou J, Fan J, Fu X, Ding Z. SQSTM1/p62 in intrahepatic cholangiocarcinoma promotes tumor progression via epithelial-mesenchymal transition and mitochondrial function maintenance. Cancer Med 2023;12:459-71. [PMID: 35676831 DOI: 10.1002/cam4.4908] [Reference Citation Analysis]
|
| 42 |
Wu W, Wang M, Li C, Zhu Z, Zhang Y, Wu D, Ou Z, Liu Z. LncRNA Snhg1 Plays an Important Role via Sequestering rno-miR-139-5p to Function as a ceRNA in Acute Rejection After Rat Liver Transplantation Based on the Bioinformatics Analysis. Front Genet 2022;13:827193. [DOI: 10.3389/fgene.2022.827193] [Reference Citation Analysis]
|
| 43 |
Huang CS, Zhu YQ, Xu QC, Chen S, Huang Y, Zhao G, Ni X, Liu B, Zhao W, Yin XY. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation. Clin Transl Med 2022;12:e848. [PMID: 35696608 DOI: 10.1002/ctm2.848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 44 |
Li J, Lu J, Lv S, Sun S, Liu C, Xu F, Sun H, Yang J, Wang X, Zhong X, Lu J. Linoleic acid pathway disturbance contributing to potential cancerization of intrahepatic bile duct stones into intrahepatic cholangiocarcinoma. BMC Gastroenterol 2022;22:269. [PMID: 35637430 DOI: 10.1186/s12876-022-02354-2] [Reference Citation Analysis]
|
| 45 |
Su L, Huang Y, Zheng L, Zhu Z, Wu Y, Li P. Isocitrate dehydrogenase 1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis. Open Medicine 2022;17:863-70. [DOI: 10.1515/med-2022-0477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 46 |
Faria LL, Darce GF, Bordini AL, Herman P, Jeismann VB, de Oliveira IS, Ortega CD, Rocha MS. Liver Surgery: Important Considerations for Pre- and Postoperative Imaging. Radiographics 2022;42:722-40. [PMID: 35363553 DOI: 10.1148/rg.210124] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 47 |
Bian J, Fu J, Wang X, Lee J, Brar G, Escorcia FE, Cam M, Xie C, Sopper S. Characterization of Immunogenicity of Malignant Cells with Stemness in Intrahepatic Cholangiocarcinoma by Single-Cell RNA Sequencing. Stem Cells International 2022;2022:1-14. [DOI: 10.1155/2022/3558200] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 48 |
Wu Y, Hayat K, Hu Y, Yang J. Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma. Front Cell Dev Biol 2022;10:890605. [DOI: 10.3389/fcell.2022.890605] [Reference Citation Analysis]
|
| 49 |
Xing H, Tan B, Yang C, Zhang M. Incidence Trend and Competing Risk Analysis of Patients With Intrahepatic Cholangiocarcinoma: A Population-Based Study. Front Med (Lausanne) 2022;9:846276. [PMID: 35433765 DOI: 10.3389/fmed.2022.846276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 50 |
Beetz O, Timrott K. Operative Therapie des intra- und extrahepatischen cholangiozellulären Karzinoms. Onkologe 2022;28:299-307. [DOI: 10.1007/s00761-022-01116-9] [Reference Citation Analysis]
|
| 51 |
Fiz F, Jayakody Arachchige VS, Gionso M, Pecorella I, Selvam A, Wheeler DR, Sollini M, Viganò L. Radiomics of Biliary Tumors: A Systematic Review of Current Evidence. Diagnostics (Basel) 2022;12. [PMID: 35453878 DOI: 10.3390/diagnostics12040826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 52 |
Fiz F, Masci C, Costa G, Sollini M, Chiti A, Ieva F, Torzilli G, Viganò L. PET/CT-based radiomics of mass-forming intrahepatic cholangiocarcinoma improves prediction of pathology data and survival. Eur J Nucl Med Mol Imaging. [DOI: 10.1007/s00259-022-05765-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 53 |
Eguchi S, Hidaka M, Hara T, Matsushima H, Soyama A. Liver transplantation for intrahepatic and hilar cholangiocellular carcinoma: Most recent updates in the literature. Annals of Gastroent Surgery. [DOI: 10.1002/ags3.12567] [Reference Citation Analysis]
|
| 54 |
Fu Q, Liu P, Jin S, Zhang X, Liu C, Hu M, Wang Y, Zhang H, Qin T. A Metastatic Intrahepatic Cholangiocarcinoma With HPCs Features: Report of a Case. Front Oncol 2022;12:829235. [PMID: 35299731 DOI: 10.3389/fonc.2022.829235] [Reference Citation Analysis]
|
| 55 |
Rauchfuß F, Ali-deeb A, Rohland O, Dondorf F, Ardelt M, Settmacher U. Living Donor Liver Transplantation for Intrahepatic Cholangiocarcinoma. Current Oncology 2022;29:1932-8. [DOI: 10.3390/curroncol29030157] [Reference Citation Analysis]
|
| 56 |
Ardito F, Coppola A, Rinninella E, Razionale F, Pulcini G, Carano D, Cintoni M, Mele MC, Barbaro B, Giuliante F. Preoperative Assessment of Skeletal Muscle Mass and Muscle Quality Using Computed Tomography: Incidence of Sarcopenia in Patients with Intrahepatic Cholangiocarcinoma Selected for Liver Resection. J Clin Med 2022;11. [PMID: 35329856 DOI: 10.3390/jcm11061530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 57 |
McMillan RR, Javle M, Kodali S, Saharia A, Mobley C, Heyne K, Hobeika MJ, Lunsford KE, Victor DW 3rd, Shetty A, McFadden RS, Abdelrahim M, Kaseb A, Divatia M, Yu N, Nolte Fong J, Moore LW, Nguyen DT, Graviss EA, Gaber AO, Vauthey JN, Ghobrial RM. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. Am J Transplant 2022;22:823-32. [PMID: 34856069 DOI: 10.1111/ajt.16906] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 58 |
Wang Z, Zhang Y, Chen Y, Liu S, Li C, Li X. Identification of a ferroptosis-related gene signature for predicting the prognosis of cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2022;16:181-91. [PMID: 35026122 DOI: 10.1080/17474124.2022.2029700] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 59 |
Sun D, Lv G, Dong J. Liver Transplantation for Intrahepatic Cholangiocarcinoma: What Are New Insights and What Should We Follow? Front Oncol 2022;11:841694. [DOI: 10.3389/fonc.2021.841694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 60 |
Krenzien F, Nevermann N, Krombholz A, Benzing C, Haber P, Fehrenbach U, Lurje G, Pelzer U, Pratschke J, Schmelzle M, Schöning W. Treatment of Intrahepatic Cholangiocarcinoma-A Multidisciplinary Approach. Cancers (Basel) 2022;14:362. [PMID: 35053523 DOI: 10.3390/cancers14020362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 61 |
Wang XY, Zhu WW, Wang Z, Huang JB, Wang SH, Bai FM, Li TE, Zhu Y, Zhao J, Yang X, Lu L, Zhang JB, Jia HL, Dong QZ, Chen JH, Andersen JB, Ye D, Qin LX. Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities. Theranostics 2022;12:260-76. [PMID: 34987644 DOI: 10.7150/thno.63417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 62 |
Liu Y, Sun J, Qi P, Liu Y. Long non-coding RNA titin-antisense RNA1 contributes to growth and metastasis of cholangiocarcinoma by suppressing microRNA-513a-5p to upregulate stratifin. Bioengineered 2021;12:12611-24. [PMID: 34903127 DOI: 10.1080/21655979.2021.2011014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 63 |
Deng L, Chen B, Zhan C, Yu H, Zheng J, Bao W, Deng T, Zheng C, Wu L, Yang Y, Yu Z, Wang Y, Chen G. A Novel Clinical-Radiomics Model Based on Sarcopenia and Radiomics for Predicting the Prognosis of Intrahepatic Cholangiocarcinoma After Radical Hepatectomy. Front Oncol 2021;11:744311. [PMID: 34868941 DOI: 10.3389/fonc.2021.744311] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 64 |
Bekki Y, Von Ahrens D, Takahashi H, Schwartz M, Gunasekaran G. Recurrent Intrahepatic Cholangiocarcinoma - Review. Front Oncol 2021;11:776863. [PMID: 34746017 DOI: 10.3389/fonc.2021.776863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 65 |
Saffioti F, Mavroeidis VK. Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis. World J Gastrointest Oncol 2021; 13(10): 1336-1366 [PMID: 34721770 DOI: 10.4251/wjgo.v13.i10.1336] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 66 |
Zori AG, Yang D, Draganov PV, Cabrera R. Advances in the management of cholangiocarcinoma. World J Hepatol 2021;13:1003-18. [PMID: 34630871 DOI: 10.4254/wjh.v13.i9.1003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 67 |
Safarpour AR, Askari H, Ejtehadi F, Azarnezhad A, Raeis-Abdollahi E, Tajbakhsh A, Abazari MF, Tarkesh F, Shamsaeefar A, Niknam R, Sivandzadeh GR, Lankarani KB, Ejtehadi F. Cholangiocarcinoma and liver transplantation: What we know so far? World J Gastrointest Pathophysiol 2021; 12(5): 84-105 [PMID: 34676129 DOI: 10.4291/wjgp.v12.i5.84] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 68 |
Sarwar A, Ali A, Ljuboja D, Weinstein JL, Shenoy-Bhangle AS, Nasser IA, Morrow MK, Faintuch S, Curry MP, Bullock AJ, Ahmed M. Neoadjuvant Yttrium-90 Transarterial Radioembolization with Resin Microspheres Prescribed Using the Medical Internal Radiation Dose Model for Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol 2021;32:1560-8. [PMID: 34454031 DOI: 10.1016/j.jvir.2021.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 69 |
Sposito C, Droz Dit Busset M, Virdis M, Citterio D, Flores M, Bongini M, Niger M, Mazzaferro V. The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: A review. Eur J Surg Oncol 2021:S0748-7983(21)00679-X. [PMID: 34412956 DOI: 10.1016/j.ejso.2021.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 70 |
Kaibori M, Yoshii K, Kashiwabara K, Kokudo T, Hasegawa K, Izumi N, Murakami T, Kudo M, Shiina S, Sakamoto M, Nakashima O, Matsuyama Y, Eguchi S, Yamashita T, Takayama T, Kokudo N, Kubo S. Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: Report of a Japanese nationwide survey. Hepatol Res 2021;51:890-901. [PMID: 34041804 DOI: 10.1111/hepr.13676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 71 |
Yang F, Wu C, Bo Z, Xu J, Yi B, Li J, Qiu Y. The clinical value of regional lymphadenectomy for intrahepatic cholangiocarcinoma. Asian J Surg 2021:S1015-9584(21)00371-7. [PMID: 34340896 DOI: 10.1016/j.asjsur.2021.06.031] [Reference Citation Analysis]
|
| 72 |
Kriss M, Biggins SW. Evaluation and selection of the liver transplant candidate: updates on a dynamic and evolving process. Curr Opin Organ Transplant 2021;26:52-61. [PMID: 33278150 DOI: 10.1097/MOT.0000000000000829] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 73 |
Fragkou N, Sideras L, Panas P, Emmanouilides C, Sinakos E. Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence? World J Gastroenterol 2021; 27(27): 4252-4275 [PMID: 34366604 DOI: 10.3748/wjg.v27.i27.4252] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 74 |
Rafecas A, Torras J, Fabregat J, Lladó L, Secanella L, Busquets J, Serrano T, Ramos E. Intrahepatic cholangiocarcinoma: Prognostic factors for recurrence and survival in a series of 67 patients treated surgically at a single center. Cir Esp (Engl Ed) 2021;99:506-13. [PMID: 34229980 DOI: 10.1016/j.cireng.2021.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 75 |
Yu H, Wang M, Wang Y, Yang J, Deng L, Bao W, He B, Lin Z, Chen Z, Chen K, Zhang B, Liu F, Yu Z, Ye L, Jin B, Chen G. The prognostic value of sarcopenia combined with preoperative fibrinogen-albumin ratio in patients with intrahepatic cholangiocarcinoma after surgery: A multicenter, prospective study. Cancer Med 2021;10:4768-80. [PMID: 34105304 DOI: 10.1002/cam4.4035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 76 |
Panayotova G, Guerra J, Guarrera JV, Lunsford KE. The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2428. [PMID: 34070772 DOI: 10.3390/jcm10112428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 77 |
Wabitsch S, Tandon M, Ruf B, Zhang Q, McCallen JD, McVey JC, Ma C, Green BL, Diggs LP, Heinrich B, Greten TF. Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice. Cell Mol Gastroenterol Hepatol 2021;12:1166-78. [PMID: 34033968 DOI: 10.1016/j.jcmgh.2021.05.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 78 |
Jones O, Cheng X, Murthy SRK, Ly L, Zhuang T, Basadonna G, Keidar M, Canady J. The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro. Sci Rep 2021;11:8967. [PMID: 33903679 DOI: 10.1038/s41598-021-88451-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 79 |
Fiste O, Ntanasis-Stathopoulos I, Gavriatopoulou M, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. Vaccines (Basel) 2021;9:422. [PMID: 33922362 DOI: 10.3390/vaccines9050422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 80 |
Reese T, Pagel G, Bause BA, von Rittberg Y, Wagner KC, Oldhafer KJ. Complex Liver Resections for Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:1672. [PMID: 33924732 DOI: 10.3390/jcm10081672] [Reference Citation Analysis]
|
| 81 |
Ziogas IA, Esagian SM, Giannis D, Hayat MH, Kosmidis D, Matsuoka LK, Montenovo MI, Tsoulfas G, Geller DA, Alexopoulos SP. Laparoscopic versus open hepatectomy for intrahepatic cholangiocarcinoma: An individual patient data survival meta-analysis. Am J Surg 2021:S0002-9610(21)00210-5. [PMID: 33840443 DOI: 10.1016/j.amjsurg.2021.03.052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 82 |
Wang Z, Jin Y, Guo Y, Tan Z, Zhang X, Ye D, Yu Y, Peng S, Zheng L, Li J. Conversion Therapy of Intrahepatic Cholangiocarcinoma Is Associated with Improved Prognosis and Verified by a Case of Patient-Derived Organoid. Cancers (Basel) 2021;13:1179. [PMID: 33803322 DOI: 10.3390/cancers13051179] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 83 |
Ren A, Li Z, Cheng P, Zhang X, Deng R, Ma Y. Systemic Immune-Inflammation Index Is a Prognostic Predictor in Patients with Intrahepatic Cholangiocarcinoma Undergoing Liver Transplantation. Mediators Inflamm 2021;2021:6656996. [PMID: 33628115 DOI: 10.1155/2021/6656996] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 84 |
Kawasaki H, Akazawa Y, Razumilava N. Progress toward improving outcomes in patients with cholangiocarcinoma. Curr Treat Options Gastroenterol 2021;19:153-68. [PMID: 33883870 DOI: 10.1007/s11938-021-00333-2] [Reference Citation Analysis]
|
| 85 |
Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet 2021;397:428-44. [PMID: 33516341 DOI: 10.1016/S0140-6736(21)00153-7] [Cited by in Crossref: 216] [Cited by in F6Publishing: 163] [Article Influence: 108.0] [Reference Citation Analysis]
|
| 86 |
Hue JJ, Rocha FG, Ammori JB, Hardacre JM, Rothermel LD, Chavin KD, Winter JM, Ocuin LM. A comparison of surgical resection and liver transplantation in the treatment of intrahepatic cholangiocarcinoma in the era of modern chemotherapy: An analysis of the National Cancer Database. J Surg Oncol 2021;123:949-56. [PMID: 33400841 DOI: 10.1002/jso.26370] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 87 |
Gunasekaran G, Bekki Y, Lourdusamy V, Schwartz M. Surgical Treatments of Hepatobiliary Cancers. Hepatology 2021;73 Suppl 1:128-36. [PMID: 32438491 DOI: 10.1002/hep.31325] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 25.5] [Reference Citation Analysis]
|
| 88 |
Zhu H, Wang L, Wang M, He X, Xu W, Zhu W, Zhao Y, Wang L. Prognostic value of resection margin length after surgical resection for intrahepatic cholangiocarcinoma. Am J Surg 2021;222:383-9. [PMID: 33388133 DOI: 10.1016/j.amjsurg.2020.12.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 89 |
Moris D, Shaw BI, McElroy L, Barbas AS. Using Hepatocellular Carcinoma Tumor Burden Score to Stratify Prognosis after Liver Transplantation. Cancers (Basel) 2020;12:E3372. [PMID: 33202588 DOI: 10.3390/cancers12113372] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 90 |
Laing RW, Mirza DF. Liver lesions: types, risk factors, investigations and treatment. Trends Urology & Men Health 2020;11:20-25. [DOI: 10.1002/tre.777] [Reference Citation Analysis]
|
| 91 |
Li F, Chen Q, Xue H, Zhang L, Wang K, Shen F. LncRNA MNX1-AS1 promotes progression of intrahepatic cholangiocarcinoma through the MNX1/Hippo axis. Cell Death Dis 2020;11:894. [PMID: 33093444 DOI: 10.1038/s41419-020-03029-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 92 |
Rafecas A, Torras J, Fabregat J, Lladó L, Secanella L, Busquets J, Serrano T, Ramos E. Intrahepatic cholangiocarcinoma: Prognostic factors for recurrence and survival in a series of 67 patients treated surgically at a single center. Cir Esp 2021;99:506-13. [PMID: 32921420 DOI: 10.1016/j.ciresp.2020.07.003] [Reference Citation Analysis]
|
| 93 |
Bartolini I, Risaliti M, Fortuna L, Agostini C, Ringressi MN, Taddei A, Muiesan P. Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments. Radiol Oncol 2020;54:263-71. [PMID: 32726292 DOI: 10.2478/raon-2020-0045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 94 |
Mohr R, Özdirik B, Knorr J, Wree A, Demir M, Tacke F, Roderburg C. In Vivo Models for Cholangiocarcinoma-What Can We Learn for Human Disease? Int J Mol Sci 2020;21:E4993. [PMID: 32679791 DOI: 10.3390/ijms21144993] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 95 |
Zhou TY, Zhou GH, Zhang YL, Nie CH, Zhu TY, Wang HL, Chen SQ, Wang BQ, Yu ZN, Wu LM, Zheng SS, Sun JH. Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma. J Cancer 2020;11:4534-41. [PMID: 32489470 DOI: 10.7150/jca.39410] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 96 |
Gringeri E, Gambato M, Sapisochin G, Ivanics T, Lynch EN, Mescoli C, Burra P, Cillo U, Russo FP. Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology. J Clin Med 2020;9:E1353. [PMID: 32380750 DOI: 10.3390/jcm9051353] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 97 |
Su L, Zhang X, Zheng L, Wang M, Zhu Z, Li P. Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism. Front Endocrinol (Lausanne) 2020;11:189. [PMID: 32373065 DOI: 10.3389/fendo.2020.00189] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 98 |
Tang Y, Yang J, Wang Y, Tang Z, Liu S, Tang Y. MiR-19b-3p facilitates the proliferation and epithelial-mesenchymal transition, and inhibits the apoptosis of intrahepatic cholangiocarcinoma by suppressing coiled-coil domain containing 6. Arch Biochem Biophys 2020;686:108367. [PMID: 32315652 DOI: 10.1016/j.abb.2020.108367] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 99 |
Zheng SS, Yang Z, Wu YC. Liver transplantation for intrahepatic and perihilar cholangiocarcinoma: Current and future. Hepatobiliary Pancreat Dis Int 2020;19:101-2. [PMID: 32165068 DOI: 10.1016/j.hbpd.2020.02.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 100 |
Li C, Xu J. Identification of Potentially Therapeutic Target Genes of Hepatocellular Carcinoma. Int J Environ Res Public Health 2020;17:E1053. [PMID: 32046048 DOI: 10.3390/ijerph17031053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
